Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find a more effective treatment for allergic fungal
rhinosinusitis (AFRS). Most people suffering from nasal polyps have elevated levels of white
blood cells called eosinophils that are involved in inflammation of the air passages. Despite
appropriate treatment with oral/topical corticosteroids, saline irrigations, and surgery,
nasal polyps return frequently within months of surgery.
Certain proteins made by the body called interleukins, appear to play a major role in the
survival and activation of eosinophils. Antibodies are proteins naturally produced by your
body that find foreign substances such as bacteria, fungi, viruses, and other substances that
enter your body and make them inactive. Dupilumab is an antibody made in the laboratory that
has been made to block specific interleukins from activating the eosinophils. This research
is being done to find out if the medication dupilumab is effective and safe when used to
treat patients with AFRS following recommended sinus surgery. Dupilumab is already approved
for the treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal
polyposis (CRSwNP); however, it is not approved to treat AFRS. Therefore its use in this
study is considered experimental.